Conflict of Interest
ONCOLOGY
Benjamin Tan reported research funding from Exelexis Bristol Myers Squibb, Eisai, Adaptimmune Therapeutics, Merck, Agios, and AstraZeneca. Katrina S. Pedersen reported scientific advisory board relationships with Novartis, Taiho, GlaxoSmithKline, AbbVie, and Arcus, and research funding from BioLine Rx, BMS, Boston Biomedical, Daiichi Sankyo, Incyte, Merck, Natera, Nouscom, Pfizer, Rafael, and Roche/Genentech. Deborah Knoerzer, Brent Kreider, and Anupama Reddy were employed by BioMed Valley Discoveries. Channing J. Der is a consultant/advisory board member for Anchiano Therapeutics, Deciphera Pharmaceuticals, Mirati Therapeutics, Revolution Medicines, SHY Therapeutics, and Verastem Oncology, has received research funding support from Deciphera Pharmaceuticals, Mirati Therapeutics, Revolution Medicines, and SpringWorks Therapeutics, and has consulted for Eli Lilly, Jazz Therapeutics, Ribometrix, Sanofi, and Turning Point Therapeutics. Andrea Wang-Gillam is currently on sabbatical from Washington University and employed by Jacobio Pharmaceuticals, Inc. The other authors indicated no financial relationships.